Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has a documented diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy, classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy or wild-type ATTR (wtATTR) amyloidosis with cardiomyopathy meeting pre-specified diagnostic criteria
Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF OR clinical evidence of HF
You may not be if
Has known primary amyloidosis or leptomeningeal amyloidosis
Has New York Heart Association (NYHA) Class IV heart failure
Has NYHA Class III heart failure AND is at high risk based on pre-specified criteria
Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Screening visit
Has estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m\^2
Has received prior TTR-lowering treatment
Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to valvular heart disease, or cardiomyopathy due to ischemic heart disease
